These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25629154)

  • 21. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
    Blake KV; Devries CS; Arlett P; Kurz X; Fitt H;
    Pharmacoepidemiol Drug Saf; 2012 Jul; 21(7):690-696. PubMed ID: 22522622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethics committees: decisions by bureaucracy.
    Siegler M
    Hastings Cent Rep; 1986 Jun; 16(3):22-4. PubMed ID: 3721844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory aspects of clinical trials in children.
    Mentzer D
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():203-7; discussion 207-9. PubMed ID: 20799462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electronic referrals: what matters to the users.
    Warren J; Gu Y; Day K; White S; Pollock M
    Stud Health Technol Inform; 2012; 178():235-41. PubMed ID: 22797047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Zealand general practitioners' non-urgent referrals to surgeons: who and why?
    Raymont A; Morgan S; McLeod D; Dowell A; van Rij A; Cumming J; Pledger M; Dew K; Cormack D
    N Z Med J; 2008 Jun; 121(1275):57-64. PubMed ID: 18551154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Family physicians' referral decisions: results from the ASPN referral study.
    Forrest CB; Nutting PA; Starfield B; von Schrader S
    J Fam Pract; 2002 Mar; 51(3):215-22. PubMed ID: 11978231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of user safety, exposure and risk to veterinary medicinal products in the European Union.
    Woodward KN
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):114-28. PubMed ID: 18060673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nimesulide controversy: a comparison of EU and Indian scenario.
    Kshirsagar NA; Bachhav SS
    Int J Risk Saf Med; 2013; 25(4):239-46. PubMed ID: 24305563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How many referrals to a pediatric orthopaedic hospital specialty clinic are primary care problems?
    Hsu EY; Schwend RM; Julia L
    J Pediatr Orthop; 2012; 32(7):732-6. PubMed ID: 22955539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additional risk minimisation measures in the EU - are they eligible for assessment?
    Zomerdijk IM; Trifirò G; Sayed-Tabatabaei FA; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1046-53. PubMed ID: 23946274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C.
    Horsfall L; Macdonald G; Scott I; Skoien R; Khatun M; Moss C; Seligman C; Kardash C; Poxon V; Powell EE
    Aust Health Rev; 2013 May; 37(2):218-22. PubMed ID: 23448666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of general practitioner referrals to outpatient departments: assessment by specialists and a general practitioner.
    Jenkins RM
    Br J Gen Pract; 1993 Mar; 43(368):111-3. PubMed ID: 8323788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee.
    Arlett P; Portier G; de Lisa R; Blake K; Wathion N; Dogne JM; Spooner A; Raine J; Rasi G
    Nat Rev Drug Discov; 2014 May; 13(5):395-7. PubMed ID: 24751815
    [No Abstract]   [Full Text] [Related]  

  • 39. Referral sources in home healthcare.
    Chromiak DM
    J Nurs Adm; 1992 Dec; 22(12):39-45. PubMed ID: 1469486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficiency of triaging low urgent self-referred patients to a general practitioner at an acute care post: an observational study.
    van der Straten LM; van Stel HF; Spee FJ; Vreeburg ME; Schrijvers AJ; Sturms LM
    Emerg Med J; 2012 Nov; 29(11):877-81. PubMed ID: 22158535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.